Clinical TrialJul 13, 2026, 08:02 AM
Aligos Completes Enrollment for Phase 2 B-SUPREME HBV Study
AI Summary
Aligos Therapeutics, Inc. announced the completion of enrollment for both HBeAg+ (Part 1a) and HBeAg- (Part 2a) participants in its global Phase 2 B-SUPREME study of pevifoscorvir sodium. This drug is being developed for the treatment of chronic hepatitis B virus (HBV) infection. The study enrolled 131 HBeAg+ and 114 HBeAg- participants, with topline safety and efficacy data anticipated in late third quarter of 2027.
Key Highlights
- Aligos completed enrollment for Phase 2 B-SUPREME study of pevifoscorvir sodium.
- Part 1a (HBeAg+) enrolled 131 participants, exceeding initial target.
- Part 2a (HBeAg-) enrolled 114 participants.
- Topline safety and efficacy data are expected in late Q3 2027.
- Pevifoscorvir sodium is an oral capsid assembly modulator (CAM-E) for HBV.
- The study evaluates pevifoscorvir sodium monotherapy vs. tenofovir disoproxil fumarate.
Price Impact
More from ALGS